Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)

Stifel analyst Alex Thompson reiterated a Buy rating and $95.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE).

The analyst commented: "We are reiterating our Buy Rating on APGE following its 3Q24 update. Most of the valuation/investor interest, in our view, remains on the prospects of APG777 (IL-13) in Atopic Dermatitis (AD) with Ph2 data on track for 2H25. While we continue to see meaningful upside to shares from APG777, we also think that the breadth of the pipeline remains largely underappreciated. 4Q24 Ph1 data for second program, APG808, (IL-4Ra) and a broader R&D day (Dec 2) represent near-term updates with the potential to drive pipeline momentum heading into 2025. Next year's catalyst path is busy: not only will we see APG777 Ph2 data, but also initial PoC data for APG808 in Asthma and initiation of a combo study of APG777+APG990 (OX40L) and more. This comes on the backdrop of key launches from Dupixent in COPD and Ebglyss in AD that could provide further positive readthrough to the APGE pipeline."

For an analyst ratings summary and ratings history on Apogee Therapeutics Inc click here. For more ratings news on Apogee Therapeutics Inc click here.

Shares of Apogee Therapeutics Inc closed at $60.46 yesterday.

You May Also Be Interested In

• Citi raises EquipmentShare price target to $22, keeps Neutral
• Target (TGT) PT Raised to $170 at Telsey
• HSBC Downgrades Cisco (CSCO) to Hold